Organizing & Scientific Committees 3
Preliminary program 4
Wednesday, December 4 4
Thursday, December 5 4
Friday, December 6 6
Saturday, December 7 9
Registration / Accommodations 11
CTAD Organizing Committee

Jacques Touchon MD, PhD
University
Hospital of Montpellier
France

Paul Aisen MD
Alzheimer’s
Therapeutic Research Institute (ATRI)
University of Southern California (USC),
San Diego, USA

Bruno Vellas MD, PhD
University
Hospital of Toulouse
France

Mike Weiner MD
University of California
San Francisco (UCSF)
USA

CTAD Scientific Committee

Susan ABUSHAKRA (San Francisco); Paul AISEN (San Diego); Kaj BLENNOW (Molndal); Merce BOADA (Barcelona); Maria CARRILLO (Chicago); Mony John DE LEON (New York); Steven DEKOSKY (Gainesville); Rachelle DOODY (Basel); Bruno DUBOIS (Paris); Howard FELDMAN (San Diego); Nick FOX (London); Giovanni B. FRISONI (Brescia, Geneva); Lutz FROELICH (Mannheim); Serge GAUTHIER (Montreal); Ezio GIACOBINI (Geneva); Michael GRUNDMANN (San Diego); Harald HAMPEL (Woodcliff Lake); Takeshi IWATSUBO (Tokyo); Ara KHACHATURIAN (Washington DC); Zaven KHACHATURIAN (Washington DC); Virginia LEE (Philadelphia); Constantine G. LYKETSOS (Baltimore); José Luis MOLINUEVO (Barcelona); Jean-Marc ORGOGOZO (Bordeaux); Ronald PETERSEN (Rochester); Craig W. RITCHIE (Edinburgh); Augustin RUIZ (Barcelona); Robert RISSMAN (San Diego); Marwan SABBAGH (Las Vegas); Stephen SALLOWAY (Providence); Rachel SCHINDLER (New York); Philip SCHELTENS (Amsterdam); Lon SCHNEIDER (Los Angeles); Eric SIEMERS (Philadelphia); Peter SYNDER (Rhode Island); Reisa SPERLING (Boston); Yaakov STERN (New York); Jacques TOUCHON (Montpellier); John TROJANOWSKI (Philadelphia); Bruno VELLAS (Toulouse); Michael W. WEINER (San Francisco); Bengt WINBLAD (Stockholm)
Wednesday, DECEMBER 4

4.00 p.m  Opening Ceremony and CTAD Lifetime Achievement Award
Paul Aisen, Jacques Touchon, Bruno Vellas, Mike Weiner

4.30 p.m  KEYNOTE 1
How to interpret recent failures for the Beta-Amyloid target?
Stephen Salloway, MD, MS - Chief of Neurology and Director of the Memory and Aging Program, Butler Hospital, Providence, RI, USA

5.00 p.m  SYMPOSIUM 1
New Results on the Relationship between Intensive Blood Pressure Control and Cognitive Function from SPRINT-MIND
Chair: Kristine Yaffe, University of California at San Francisco (UCSF), San Francisco, CA, USA
PRESENTATION 1: Effect of intensive blood pressure control on subtypes of mild cognitive impairment
Sarah Gaussoin, Wake Forest School of Medicine, Winston-Salem, NC, USA
PRESENTATION 2: Lessons Learned from Cognitive Outcomes in SPRINT: Neuropsychological Test Scores, Domain-Specific Cognitive Function, and Adjudicated Outcomes
Nicholas M. Pajewski, Wake Forest School of Medicine, Winston-Salem, NC, USA
PRESENTATION 3: Effect of intensive blood pressure control on brain MRI biomarkers
Ilya Nasrallah, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

6.00 p.m  LATE BREAKING ORAL COMMUNICATIONS

Thursday, DECEMBER 5

8.00 a.m  LATE BREAKING ORAL COMMUNICATIONS

9.00 a.m  ORAL COMMUNICATIONS SESSION

9.00 a.m  OC1 - Comparative Effectiveness of behavioral interventions in Mild Cognitive Impairment: 12-month outcomes of a Randomized Clinical Trial
Glenn Smith, University of Florida, Gainesville, FL, USA

9.15 a.m  OC2 - AADvac1 tau vaccine completing the phase 2 study: a paradigm shift for the AD treatment hypothesis
Matej Ondrus, AXON Neuroscience CRM Services SE, Bratislava, Slovakia
9.30 a.m  OC3 - Treatment with Donanemab, a β-amyloid plaque-specific antibody, results in rapid and sustained reduction of amyloid measured by F-18 florbetapir imaging in Alzheimer’s disease
Stephen Lowe, Lilly Centre for Clinical Pharmacology, Singapore, Singapore

9.45 a.m  OC4 - Automatic speech recognition can deliver large-scale, remote assessments of cognition
Francesca Cormack PhD (1,2), Merina Su PhD (1), Jennifer H. Barnett PhD (1,2), Nick Taptiklis (1)

10.00 a.m Coffee Break and poster sessions

10.30 a.m  SYMPOSIUM 2
New Predictive Platforms for Advancing Drug Combination Approaches for Alzheimer Pathology
Chairman: Lon Schneider, Keck School of Medicine of USC, Los Angeles, CA, USA

PRESENTATION 1: In Silico Screening of Medications for Slowing Alzheimer’s Disease Progression in a Clinical Trials Meta-database
Richard E. Kennedy, University of Alabama, Birmingham, AL, USA

PRESENTATION 2: Drug Combination Identification through Correlation between a Clinical Dataset and a Computational Model
Thomas J. Anastasio, University of Illinois at Urbana-Champaign, Urbana, IL, USA

PRESENTATION 3: Evaluating Pharmacodynamic Interactions in Drug Combinations Using Quantitative Systems Pharmacology Analysis of Clinical Trials
Hugo Geerts, In Silico Biosciences, Berwyn, PA, USA

11.30 a.m ORAL COMMUNICATIONS SESSION

11.30 a.m  OC5 - Development of cognitive go/no-go decision-making criteria in early clinical development of agents to treat Alzheimer’s disease
Alette Wessels, PhD (1), Chris J. Edgar PhD (2), Gregory Light, PhD (3), Pradeep Nathan, PhD (4), Eric Siemers, MD (5), Paul Maruff, PhD (6), John Harrison, PhD (7)
(1) Eli Lilly and Company, Indianapolis, IN, USA, (2) Cogstate Ltd, London, UK, (3) Department of Psychiatry, University of California, San Diego, USA, (4) Sosei-Heptares, Cambridge, UK; Department of Psychiatry, University of Cambridge UK; School of Psychological Sciences, Monash University, Australia, (5) Cogstate Ltd, New Haven, CT, USA, (6) Cogstate Ltd., Melbourne, Australia, (7) Metis Cognition Ltd, Kilmington Common, UK; Alzheimer Center AUMc, Amsterdam, The Netherlands; Institute of Psychiatry, Psychology & Neuroscience, King’s College London, UK

11.45 a.m  OC6 - Efficacy and safety results of REVERSE-SD, phase-2b clinical study of the selective p38α kinase inhibitor neflamapimod in early-stage Alzheimer’s disease (AD)
Philip Scheltens, Alzheimer Center, Amsterdam UMC, Amsterdam, The Netherlands

12.00 p.m  OC7 - Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimer’s disease (CREAD/CREAD2): Biomarker results
Tobias Bittner, F. Hoffmann-La Roche Ltd, Basel, Switzerland

12.15 p.m  OC8 - DHA Brain Delivery Pilot Study: A randomized clinical trial
Hussein Yassine, USC, Los Angeles, CA, USA

12.30 p.m Lunch and Poster Sessions

1.30 p.m  KEYNOTE 2
Overview of the NIA portfolio in AD clinical trials: Which new targets could be explored?
Eliezer Masliah, MD - Director of the Division of Neuroscience, National Institute on Aging (NIA), Bethesda, USA
Thursday,
DECEMBER 5

2.00 p.m

ROUNDTABLE
Pros and Cons of Weighted Composite Scores for Preclinical and Prodromal Alzheimer’s Disease
Moderators: Sandrine Andrieu MD, PhD, Inserm, University of Toulouse, Toulouse, France, Pierre Tariot MD, Banner Alzheimer Institute, Phoenix, AZ, USA

PRESENTATION 1: Important Considerations for Statistically Deriving Weighted Composite Scores for Alzheimer’s Disease
Suzanne Hendrix, Pentara Corp, Salt Lake City, UT, USA

PRESENTATION 2: The Weighting Game: What Impact Do Weights Have on Composite Scores - Are They Worth It?
Kun Jin, Statistical Team Leader, US Food and Drug Administrations, Washington, DC, USA

3.30 p.m

Coffee Break and poster sessions

4.00 p.m

SYMPOSIUM 3
Epigenetics and the BET-system in vascular dementia, Alzheimer’s disease and mixed dementia – the problem and potential remedies
Chairman: Bengt Winblad, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden

PRESENTER 1: Dementias, who and how to treat and by what specialty. Addressing problem and current and potential future therapeutic practices
Charles DeCarli, MD, FAAN, FAHA, UC Davis, CA, USA

PRESENTER 2: Fluid biomarkers that predict and project brain health
Henrik Zetterberg, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

PRESENTER 3: The epigenetic inhibitor APABETALONE corrects pathophysiological brain endothelial and microglial cell activation that contributes to neurodegenerative disease
Ewelina Kulikowska, SVP Research and Development, Resverlogix Corporation, Calgary, Canada

PRESENTER 4: Epigenetics, the BET-system, Alzheimer’s Disease and Vascular Cognitive Impairment. The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease
Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

5.00 p.m

LATE BREAKING ORAL COMMUNICATIONS
Friday, DECEMBER 6

8.00 a.m LATE BREAKING ORAL COMMUNICATIONS

9.00 a.m ORAL COMMUNICATIONS SESSION

9.00 a.m OC9 - Anchor- and Distribution-based methods to establish clinically meaningful score changes on the Clinical Dementia Rating Scale – Sum of Boxes in patients with prodromal Alzheimer’s Disease
Claire Lansdall, Roche Products Limited, Welwyn Garden City, UK

9.15 a.m OC10 - Awareness of Genetic Risk in the Dominantly Inherited Alzheimer Network (DIAN)
Jason Hassenstab, Washington University in St. Louis, MO, USA

9.30 a.m OC11 - Umibecestat: a BACE1 inhibitor continuing to assess potential for AD prevention in the Generation Program
Ana Graf, Novartis Pharma, Basel, Switzerland

9.45 a.m OC12 - Recruitment Strategies for the Generation Program AD Prevention Clinical Trials: Lessons from the Butler Hospital Memory & Aging Program
Jessica Alber, University of Rhode Island, Kingston, RI, USA

10.00 a.m Coffee Break and poster sessions

10.30 a.m KEYNOTE 3
Failure after failure, what’s next in AD Drug Development?
Paul Aisen, MD - Director of the Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, USC, San Diego, CA, USA

11.00 a.m SYMPOSIUM 4
AMBAR (Alzheimer’s Management By Albumin Replacement) Phase 2B/3 Trial: complete clinical, biomarker and neuroimaging results
Chairman: Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, USA

PRESENTERS:
Antonio Páez, Grifols, Barcelona, Spain

12.00 p.m Lunch and poster sessions

1.00 p.m ORAL COMMUNICATIONS SESSION

1.00 p.m OC13 - Thirty-six-month amyloid PET results show continued reduction in amyloid burden with gantenerumab
Gregory Klein, Roche Pharma Research and Early Development, Basel, Switzerland

1.15 p.m OC14 - A Phase 1 Study of ALO02 in Healthy Volunteers and Patients With Mild-To-Moderate Alzheimer’s Disease
Robert Paul, Alector, Inc., South San Francisco, CA, USA

1.30 p.m OC15 - Predicting sporadic Alzheimer’s progression via inherited Alzheimer’s-informed machine learning
Nicolai Franzmeier, Ludwig Maximilians University, Institute for Stroke and Dementia Research, Munich, Germany
Friday, DECEMBER 6

ORAL COMMUNICATIONS SESSION

1.45 p.m  
OC16 - Continuously Acquired, Home-Based Digital Biomarkers of Activity and Function Are Related to Alzheimer’s Disease Neupathology  
Jeffrey Kaye, Oregon Health & Science University, Portland, OR, USA

2.00 p.m  
OC17 - The Alzheimer’s Clinical Trials Consortium Seeks Partners for Therapeutic Trials  
Sarah Walter, Alzheimer's Therapeutic Research Institute (ATRI), University of Southern California, San Diego, USA

2.15 p.m  
OC18 - The EXERT Trial: Testing a Model for Effective Community-Based Exercise Intervention Delivery for Adults with MCI  
Jeffrey Katula, Wake Forest School of Medicine, Winston-Salem, NC, USA

2.30 p.m  
OC19 - The effects of rasagiline upon cerebral glucose metabolism, cognition, and tau in patients with mild to moderate Alzheimer’s disease: Results of a Phase II clinical trial  
Dawn Matthews, ADM Diagnostics Inc, Northbrook, IL, USA

2.45 p.m  
OC20 - Towards a flurbiprofen-based dual -biomarker screening strategy  
Sergey Shcherbinin, Eli Lilly & Company, Indianapolis, IN, USA

3.00 p.m  
KEYNOTE 4  
Next generation of multidomain lifestyle clinical trials: Design and implementation for proof of scientific concept and pragmatic sustainability  
Laura D. Baker, PhD - Associate Professor, Gerontology and Geriatric Medicine, Wake Forest School Medicine, Winston-Salem, NC, USA

3.30 p.m  
Coffee Break and poster sessions

4.00 p.m  
OC21 - FCSRT inclusion criteria support recruitment of a population with early Alzheimer’s disease likely to progress over 24 months: results from the CREAD trial  
Kaycee Sink, Genentech, Inc., South San Francisco, CA, USA

4.15 p.m  
OC22 - Assessing in Power in Phase II Proof-of-Concept Trials in Prodromal Alzheimer’s Disease  
Michelle Nuno, Department of Statistics, University of California, Irvine, CA, USA

4.30 p.m  
OC23 - The Alzheimer’s disease THErapy with NEuroaid (ATHENE) Study: Assessing the Safety and Efficacy of Neuroaid II (MLC901) in patients with mild to moderate Alzheimer’s disease stable on Cholinesterase inhibitors or Memantine: A Randomized, double blind, placebo-controlled trial: BASELINE RESULTS  
Christopher Chen, National University of Singapore, Singapore

4.45 p.m  
OC24 - Phase 1 study of NDX-1017: safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and dementia patients  
Xue Hua, Athira Pharma, Inc, Seattle, WA, USA

5.00 p.m  
LATE BREAKING ORAL COMMUNICATIONS
8.00 a.m
LATE BREAKING ORAL COMMUNICATIONS

9.00 a.m
ROUNDTABLE
Sex/gender consideration in clinical trials and potential improvements to clinical trial design
Merce Boada (1,2,3), Antonella Santuccione, (4,7), Maria Teresa Ferretti MT (4,5,6), Cassandra Szoek (8), Jennifer Ann Zimmer (9)
(1) Research Center and Memory Clinic. Fundació ACE, Institut Català de Neurociències Aplicades, (2) Universitat Internacional de Catalunya- Barcelona, Spain, (3) Networking Research Center on Neurodegenerative Disease (CIBERNED), Instituto de Salud Carlos III, Spain, (4) Women’s Brain Project, Guntershausen, Switzerland, (5) Institute for Regenerative Medicine-IREM, University of Zurich, Zurich, Switzerland, (6) Neuroscience Center Zurich (ZN2), University of Zurich, Zurich, Switzerland, (7) Global Medical and Scientific Affairs, Roche Diagnostics International Ltd., Rotkreuz, Switzerland, (8) Women’s Healthy Ageing Project, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia, (9) Eli Lilly and Company, Indianapolis, IN, USA

9.30 a.m
KEYNOTE 5 (to be confirmed)
Digital Clinical Trials: It’s Not [all] About the Tech!
Amy P. Abernethy, M.D., Ph.D - Principal Deputy Commissioner of Food and Drugs, USA

10.00 a.m Coffee Break and poster sessions

10.30 a.m
ORAL COMMUNICATIONS SESSION

10.30 a.m OC25 - Regulation of glial cell activation and neurodegeneration by anti-semaphorin 4D antibody pepinemab (VX15/2503), a potential treatment for Alzheimer’s and Huntington’s Disease
Elizabeth Evans, Vaccinex, Rochester, NY, USA

10.45 a.m OC26 - Therapeutic ultrasound as a treatment strategy for Alzheimer’s disease - preclinical data (including Aducanumab) and clinical trial design
Jürgen Götz, The University of Queensland, Queensland Brain Institute, Brisbane, Australia

11.00 a.m OC27 - Baseline Clinical and Biomarker Characteristics from a Phase 2 Trial of R07105705 in Prodromal-to-Mild Alzheimer’s Disease (Tauriel)
Edmond Teng, Genentech, South San Francisco, CA, USA

11.15 a.m OC28 - COR388, A Novel Gingipain Inhibitor, Decreases Fragmentation of ApoE in Alzheimer’s Disease Central Nervous System
Michael Detke, Cortexyme, South San Francisco, CA, USA

11.30 a.m
SYMPOSIUM 5
Alzheimer’s Disease in Down Syndrome: New Insights and Opportunities
Chairman : Michael Rafii, USC, San Diego, CA, USA

PRESENTATION 1: Cognitive markers of preclinical and prodromal Alzheimer’s disease in Down syndrome
Andre Strydom, King’s College London, London, UK

PRESENTATION 2: Neuroimaging biomarkers of AD in DS
Brad Christian, University of Wisconsin, Madison, WI, USA

PRESENTATION 3: Plasma and CSF biomarkers for the diagnosis of AD in DS
Juan Fortea, Hospital Sant Pau, Barcelona, Spain
Saturday, DECEMBER 7

12:30 p.m  Lunch and Poster Sessions

**ORAL COMMUNICATIONS SESSION**

1:30 p.m  OC29 - Binding profiles of BAN2401 and aducanumab to different amyloid-beta species  
*Lars Lannfelt*, Uppsala University, Uppsala, Sweden

1:45 p.m  OC30 - Non-GLP Toxicity and Toxicokinetics Studies of P8, a Peptide Drug Candidate for the treatment of Alzheimer’s Disease  
*Nanzeen Dewji*, Cenna Biosciences Inc., La Jolla, CA, USA

2:00 p.m  OC31 - An exploratory examination of NeuroToolKit biomarkers across AD stages  
*Carol Van Hulle*, University of Wisconsin-Madison, Madison, WI, USA

2:15 p.m  OC32 - Improving Polygenic Risk Scores for Alzheimer’s Disease  
*Samuel Dickson*, Pentara Corp., Salt Lake City, UT, USA

2:30 p.m  OC33 - Evaluating mixed effects models for burst cognitive data in Alzheimer disease clinical trials  
*Guoqiao Wang*, Washington University School of Medicine, St. Louis, MO, USA

2:45 p.m  OC34 - Safety, pharmacokinetics and pharmacodynamics of RDN-929: a potent and selective HDAC-CoREST complex inhibitor for the treatment of synaptopathies  
*J. Michael Ryan*, Rodin Therapeutics, Cambridge, MA, USA

3:00 p.m  OC35 - A Phase 2 trial of GRF6019 in mild-to-moderate Alzheimer’s disease  
*Jonas Hannestad*, Alkahest, San Carlos, CA, USA

3:15 p.m  OC36 - HOPE4MCI Trial: Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer’s Disease with AG8101  
*Sharon Rosenzweig-Lipson*, AgeneBio, Inc, Baltimore, MD, USA

3:30 p.m  OC37 - A review of volumetric MRI changes in AD treatment trials and a framework for their interpretation  
*Adam Schwarz*, Takeda, Cambridge, MA, USA

3:45 p.m  **LATE BREAKING ORAL COMMUNICATIONS**

4:30 p.m  End of conference
Registration

Early bird fees (until September 17)
- Early bird registration (no lunches) - 995 €
- Early bird registration (3 lunches) - 1124 €

Regular registration (from September 18)
- Full registration (no lunches) - 1287 €
- Full registration (3 lunches) - 1416 €

Pack of 3 lunches - 135 €

Please note that REGISTRATION TO CTAD 2019 INCLUDES:
- access to all CTAD sessions, CTAD 2019 abstracts, one-year online subscription to the Journal of Prevention of Alzheimer’s Disease (JPAD)
- and conference materials.

You can register directly on our website www.ctad-alzheimer.com

Accommodations

Book your accommodation at the Conference Venue
This year again CTAD has negotiated a special price to stay at the Hilton San Diego Bayfront where CTAD will be held.

Hilton San Diego Bayfront
1 Park Boulevard
San Diego
California, 92101

Book your room on our website www.ctad-alzheimer.com
SAN DIEGO 2019
CTAD Congress
Email: ctad@ant-congres.com
www.ctad-alzheimer.com

#CTAD2019

www.ctad-alzheimer.com

CTAD 2019
Clinical Trials on Alzheimer's Disease

Keep in touch

Follow us on

@CTADConference  CTAD Conference  CTAD Alzheimer